Celsion gets US nod for prostate cancer trial:
This article was originally published in Clinica
Executive Summary
Celsion has gained the go-ahead from the US FDA to begin clinical trials of its heat-activated drug treatment for prostate cancer. The therapy combines a focused-heat thermotherapy delivery system with a heat-sensitive liposome that is designed, when activated, to deliver a chemotherapeutic agent to the targeted tumour site. Celsion, of Columbia, Maryland has exclusive worldwide commercial licences to the heat-activated liposome technology, which was invented by Dr David Needham from Duke University in Durham, North Carolina.